# Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

> **NCT02231658** · PHASE1 · TERMINATED · sponsor: **Profil Institut für Stoffwechselforschung GmbH** · enrollment: 109 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Liraglutide
- **DRUG:** Lixisenatide

## Key facts

- **NCT ID:** NCT02231658
- **Lead sponsor:** Profil Institut für Stoffwechselforschung GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-16
- **Primary completion:** 2018-07-23
- **Final completion:** 2018-07-23
- **Target enrollment:** 109 (ACTUAL)
- **Why stopped:** Too challenging to recruit appropriate participants at an acceptable speed.
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02231658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02231658, "Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02231658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*